Carbogen Amcis restructures

Carbogen Amcis plans to restructure its Swiss operations. Early phase services will be consolidated at the company's Aarau site, while the Hunzenschwil site will focus on new technologies, such as micro-reactors and crystallisation. Late phase and high potency services at the Bubendorf facility, will be expanded, due to increased market demand. The changes would result in the loss of up to 40 positions.
Carbogen Amcis has seen a significant increase in the number and rate of progress associated with later phase projects, but there has been a substantial decline in the number of early phase projects being generated.
Dishman Pharma, Carbogen Amcis' parent company saw 2Q revenue decrease 12% mainly due to a disappointing quarter at Carbogen Amcis.
Carbogen Amcis
Money Control